FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096202952> ?p ?o ?g. }

• W2096202952 endingPage "154" @default.
• W2096202952 startingPage "146" @default.
• W2096202952 abstract "<h2>Abstract</h2> Breast cancer remains a leading cause of cancer death in women worldwide, and the risk for disease recurrence continues despite improvements in screening and treatment and the use of prophylactic estrogen-inhibiting therapies such as tamoxifen. A number of long-term studies now indicate a significant risk for breast cancer recurrence among patients who have undergone the currently recommended five years of tamoxifen adjuvant therapy following successful treatment of their initial disease. This ongoing recurrence risk extends even to patients commonly considered at low risk for relapse, that is, those with low-grade, small tumors, and/or node-negative disease. Treatment with tamoxifen for more than five years appears detrimental rather than beneficial and, therefore, tamoxifen is not indicated for use beyond the initial five years. Endometrial cancer and thromboembolism are among the serious adverse events that have been observed with long-term tamoxifen treatment. The aromatase inhibitors are able to reduce overall estrogen levels and appear to be better tolerated over a long term. Letrozole is the most potent aromatase inhibitor and has been available in Europe since 1996 and in the United States since 1997. Letrozole has been approved for first-line treatment of postmenopausal women with hormone-receptor – positive or hormone-receptor – unknown, advanced or metastatic breast cancer in the United States and Europe, as well as for neoadjuvant treatment (primary systemic therapy) of early breast cancer prior to surgery in many countries. The results of the pivotal MA-17 trial demonstrate that letrozole is unique in its ability to improve disease-free survival in breast cancer patients who have undergone tamoxifen therapy for five years. The MA-17 results indicate that extended adjuvant therapy with letrozole reduces risk of recurrence in this setting by 42%, reduces risk of distant recurrence (metastasis), and may improve patient survival in the node-positive patient population. The results also show letrozole to be well tolerated and safe over the length of follow-up. The trial outcomes have led to the approval of letrozole for the extended adjuvant indication in more than 40 countries worldwide. Re-randomization of letrozole-treated patients from this pivotal trial is underway to investigate if ten years of extended adjuvant endocrine therapy leads to further improvement, and the results of this extension study should aid in resolving several open questions regarding extended adjuvant therapy, including who should be treated and for how long." @default.
• W2096202952 created "2016-06-24" @default.
• W2096202952 creator A5035387502 @default.
• W2096202952 creator A5038243095 @default.
• W2096202952 date "2006-06-01" @default.
• W2096202952 modified "2023-10-12" @default.
• W2096202952 title "Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: Why, who and how long?" @default.
• W2096202952 cites W1562190372 @default.
• W2096202952 cites W1861968676 @default.
• W2096202952 cites W1909697168 @default.
• W2096202952 cites W1918073772 @default.
• W2096202952 cites W1932574503 @default.
• W2096202952 cites W1934173384 @default.
• W2096202952 cites W1948838904 @default.
• W2096202952 cites W1961026612 @default.
• W2096202952 cites W1966623655 @default.
• W2096202952 cites W1967494689 @default.
• W2096202952 cites W1983471313 @default.
• W2096202952 cites W1993837674 @default.
• W2096202952 cites W1995662976 @default.
• W2096202952 cites W2003726111 @default.
• W2096202952 cites W2015807835 @default.
• W2096202952 cites W2021697540 @default.
• W2096202952 cites W2023271196 @default.
• W2096202952 cites W2054266788 @default.
• W2096202952 cites W2088569458 @default.
• W2096202952 cites W2091890568 @default.
• W2096202952 cites W2107118598 @default.
• W2096202952 cites W2109250250 @default.
• W2096202952 cites W2112666042 @default.
• W2096202952 cites W2114167623 @default.
• W2096202952 cites W2121555447 @default.
• W2096202952 cites W2121656289 @default.
• W2096202952 cites W2132846837 @default.
• W2096202952 cites W2133764838 @default.
• W2096202952 cites W2139422964 @default.
• W2096202952 cites W2141647078 @default.
• W2096202952 cites W2142783428 @default.
• W2096202952 cites W2145819414 @default.
• W2096202952 cites W2151447010 @default.
• W2096202952 cites W2153247110 @default.
• W2096202952 cites W2156945893 @default.
• W2096202952 cites W2202169216 @default.
• W2096202952 cites W2341625215 @default.
• W2096202952 cites W2463167067 @default.
• W2096202952 cites W2597616474 @default.
• W2096202952 cites W2597942808 @default.
• W2096202952 cites W2604578436 @default.
• W2096202952 cites W2605204837 @default.
• W2096202952 cites W597449721 @default.
• W2096202952 doi "https://doi.org/10.1016/j.ejogrb.2006.03.006" @default.
• W2096202952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16621229" @default.
• W2096202952 hasPublicationYear "2006" @default.
• W2096202952 type Work @default.
• W2096202952 sameAs 2096202952 @default.
• W2096202952 citedByCount "9" @default.
• W2096202952 countsByYear W20962029522015 @default.
• W2096202952 countsByYear W20962029522016 @default.
• W2096202952 countsByYear W20962029522020 @default.
• W2096202952 crossrefType "journal-article" @default.
• W2096202952 hasAuthorship W2096202952A5035387502 @default.
• W2096202952 hasAuthorship W2096202952A5038243095 @default.
• W2096202952 hasConcept C121608353 @default.
• W2096202952 hasConcept C126322002 @default.
• W2096202952 hasConcept C143998085 @default.
• W2096202952 hasConcept C197934379 @default.
• W2096202952 hasConcept C2776166826 @default.
• W2096202952 hasConcept C2776215463 @default.
• W2096202952 hasConcept C2777176818 @default.
• W2096202952 hasConcept C2778504769 @default.
• W2096202952 hasConcept C2778812593 @default.
• W2096202952 hasConcept C29456083 @default.
• W2096202952 hasConcept C530470458 @default.
• W2096202952 hasConcept C71924100 @default.
• W2096202952 hasConceptScore W2096202952C121608353 @default.
• W2096202952 hasConceptScore W2096202952C126322002 @default.
• W2096202952 hasConceptScore W2096202952C143998085 @default.
• W2096202952 hasConceptScore W2096202952C197934379 @default.
• W2096202952 hasConceptScore W2096202952C2776166826 @default.
• W2096202952 hasConceptScore W2096202952C2776215463 @default.
• W2096202952 hasConceptScore W2096202952C2777176818 @default.
• W2096202952 hasConceptScore W2096202952C2778504769 @default.
• W2096202952 hasConceptScore W2096202952C2778812593 @default.
• W2096202952 hasConceptScore W2096202952C29456083 @default.
• W2096202952 hasConceptScore W2096202952C530470458 @default.
• W2096202952 hasConceptScore W2096202952C71924100 @default.
• W2096202952 hasIssue "2" @default.
• W2096202952 hasLocation W20962029521 @default.
• W2096202952 hasLocation W20962029522 @default.
• W2096202952 hasOpenAccess W2096202952 @default.
• W2096202952 hasPrimaryLocation W20962029521 @default.
• W2096202952 hasRelatedWork W1491737910 @default.
• W2096202952 hasRelatedWork W1965701270 @default.
• W2096202952 hasRelatedWork W1971410221 @default.
• W2096202952 hasRelatedWork W2007182497 @default.
• W2096202952 hasRelatedWork W2015807835 @default.
• W2096202952 hasRelatedWork W2033747658 @default.
• W2096202952 hasRelatedWork W2090744251 @default.

• next